NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Recruiting · NCT06405490 · Registry updated 2024-12-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | pancreatic adenocarcinoma | Recruiting | Phase 2 | 2024-12-24 | NCT06405490 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 294 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing | China | 3 |